Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin

Epigenetics

Volumn 8, Issue 6, 2013, Pages 656-665

  Sabatino, Maria Antonietta ^a   Geroni, Cristina ^b   Ganzinelli, Monica ^a   Ceruti, Roberta ^a,c   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PFIZER INC   (United States)

^c NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Combination chemotherapy; DNA methylation; DNA reactive agents; Prostate cancer; Reversal of drug resistance

Indexed keywords

BROSTALLICIN; GLUTATHIONE TRANSFERASE; ZEBULARINE; ANTINEOPLASTIC AGENT; CYTIDINE; GUANIDINE DERIVATIVE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE; PYRROLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROSTATE CANCER; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; DNA METHYLATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZATION; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTIDINE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; GUANIDINES; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PYRROLES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891707419     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24916     Document Type: Article

References (34)

1. Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, et al. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer 2012; 11:52; PMID:22867098; http://dx.doi.org/10.1186/1476-4598-11-52
2. Mahapatra S, Klee EW, Young CYF, Sun Z, Jimenez RE, Klee GG, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012; 18:2882-95; PMID:22589488; http://dx.doi.org/10.1158/1078-0432.CCR-11-2090
3. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58:4515-8; PMID:9788592
4. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39:166-74; PMID:10334105; http://dx.doi.org/10.1002/(SICI)1097-0045(19990515)39:3166::AID-PROS43.0.CO;2-J
5. Yoon HY, Kim YW, Kang HW, Kim WT, Yun SJ, Lee SC, et al. DNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysis. Korean J Urol 2012; 53:200-5; PMID:22468217; http://dx.doi.org/10.4111/kju.2012.53.3.200
6. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996; 56:3577-82; PMID:8758929
7. Hall AG, Matheson E, Hickson ID, Foster SA, Hogarth L. Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation. Cancer Res 1994; 54:3369-72; PMID:8012951
8. Hao XY, Bergh J, Brodin O, Hellman U, Mannervik B. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 1994; 15:1167-73; PMID:8020151; http://dx.doi.org/10.1093/carcin/15.6.1167
9. Sánchez-Gómez FJ, Díez-Dacal B, Pajares MA, Llorca O, Pérez-Sala D. Cyclopentenone prostaglandins with dienone structure promote cross-linking of the chemoresistance-inducing enzyme glutathione transferase P1-1. Mol Pharmacol 2010; 78:723-33; PMID:20631055; http://dx.doi.org/10.1124/mol.110.065391
10. Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, et al. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. J Med Chem 2004; 47:2611-23; PMID:15115402; http://dx.doi.org/10.1021/jm031051k
11. Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C. Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs 2004; 15:1-6; PMID:15090736; http://dx.doi.org/10.1097/00001813-200401000-00001
12. Cozzi P. The discovery of a new potential anticancer drug: a case history. Farmaco 2003; 58:213-20; PMID:12620417; http://dx.doi.org/10.1016/S0014-827X(03)00014-4
13. Cozzi P, Beria I, Caldarelli M, Geroni C, Mongelli N, Pennella G. Cytotoxic α-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety. Bioorg Med Chem Lett 2000; 10:1273-6; PMID:10866398; http://dx.doi.org/10.1016/S0960-894X(00)00205-5
14. Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, et al. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs 2009; 18:1939-46; PMID:19938904; http://dx.doi.org/10.1517/13543780903401284
15. Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, et al. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 2002; 62:2332-6; PMID:11956092
16. Pezzola S, Antonini G, Geroni C, Beria I, Colombo M, Broggini M, et al. Role of glutathione transferases in the mechanism of brostallicin activation. Biochemistry 2010; 49:226-35; PMID:19950984; http://dx.doi.org/10.1021/bi901689s
17. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groovebinder, brostallicin. Clin Cancer Res 2003; 9:5402-8; PMID:14614026
18. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25:4603-9; PMID:17925555; http://dx.doi.org/10.1200/JCO.2007.10.8688
19. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60:6039-44; PMID:11085525
20. Watanabe YOH, Ueda H, Etoh T, Koike E, Fujinami N, Mitsuhashi A, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 2007; 27(3B):1449-52; PMID:17595760
21. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18:2335-41; PMID:10327053; http://dx.doi.org/10.1038/sj.onc.1202540
22. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002; 321:591-9; PMID:12206775; http://dx.doi.org/10.1016/S0022-2836(02)00676-9
23. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95:399-409; PMID:12618505; http://dx.doi.org/10.1093/jnci/95.5.399
24. Bradbury J. Zebularine: a candidate for epigenetic cancer therapy. Drug Discov Today 2004; 9:906-7; PMID:15501719; http://dx.doi.org/10.1016/S1359-6446(04)03266-0
25. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004; 24:1270-8; PMID:14729971; http://dx.doi.org/10.1128/MCB.24.3.1270-1278.2004
26. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6:151-8; PMID:15324698; http://dx.doi.org/10.1016/j.ccr.2004.06.023
27. Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 2004; 32:910-2; PMID:15506921; http://dx.doi.org/10.1042/BST0320910
28. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 2005; 16:301-8; PMID:15711182; http://dx.doi.org/10.1097/00001813-200503000-00009
29. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010; 2:54-77; PMID:20962331; http://dx.doi.org/10.1126/scitranslmed.3001338
30. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2010; 120:581-92; PMID:19459041; http://dx.doi.org/10.1007/s10549-009-0420-3
31. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005; 11:4571-9; PMID:15958643; http://dx.doi.org/10.1158/1078-0432.CCR-05-0050
32. Meador JA, Su Y, Ravanat JL, Balajee AS. DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine. Carcinogenesis 2010; 31:184-91; PMID:19933707; http://dx.doi.org/10.1093/carcin/bgp284
33. Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol 2007; 31:1449-56; PMID:17982671
34. Champion C, Guianvarc'h D, Sénamaud-Beaufort C, Jurkowska RZ, Jeltsch A, Ponger L, et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One 2010; 5:e12388; PMID:20808780; http://dx.doi.org/10.1371/journal.pone.0012388